title: Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.
abstract: The growing incidence of serious infections mediated by methicillin-resistant Staphylococcus aureus (MRSA) strains poses a significant risk to public health. This risk is exacerbated by a prolonged void in the discovery and development of truly novel antibiotics and the absence of a vaccine. These gaps have created renewed interest in the use of biologics in the prevention and treatment of serious staphylococcal infections. In this review, we focus on efforts towards the discovery and development of antibody-based biologic agents and their potential as clinical agents in the management of serious S. aureus infections. Recent promising data for monoclonal antibodies (mAbs) targeting anthrax and Ebola highlight the potential of antibody-based biologics as therapeutic agents for serious infections.
authors.affiliation: Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
authors.forename: William E
authors.initials: WE
authors.lastname: Sause
authors.affiliation: Janssen Research & Development LLC, 1400 McKean Road, Spring House, PA 19477, USA.
authors.forename: Peter T
authors.initials: PT
authors.lastname: Buckley
authors.affiliation: Janssen Research & Development LLC, 1400 McKean Road, Spring House, PA 19477, USA.
authors.forename: William R
authors.initials: WR
authors.lastname: Strohl
authors.affiliation: Janssen Research & Development LLC, 1400 McKean Road, Spring House, PA 19477, USA. Electronic address: alynch2@its.jnj.com.
authors.forename: A Simon
authors.initials: AS
authors.lastname: Lynch
authors.affiliation: Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA. Electronic address: victor.torres@nyumc.org.
authors.forename: Victor J
authors.initials: VJ
authors.lastname: Torres
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D001685:Biological Factors / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000276:immunology*; D013203:Staphylococcal Infections / Q000276:immunology* / Q000382:microbiology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D001685:Biological Factors
keywords: MRSA; antibody; biologics; immune evasion; infectious diseases